Junbin Zhang

Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines

Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia

Single modification at position 14 of siRNA strand abolishes its gene‐silencing activity by decreasing both RISC loading and target degradation

Modification of the siRNA Passenger Strand by 5‐Nitroindole Dramatically Reduces its Off‐Target Effects